GB Patent

GB2542797A — Use of cannabinoids in the treatment of inflammatory skin diseases

Assigned to GW Pharma Ltd · Expires 2017-04-05 · 9y expired

What this patent protects

One or more cannabinoids selected from the group consisting of: cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabigerol (CBG), cannabigervarin (CBGV) and tetrahydrocannabivarin (THCV) for use in the treatment of an inflammatory skin disease is provided. …

USPTO Abstract

One or more cannabinoids selected from the group consisting of: cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabigerol (CBG), cannabigervarin (CBGV) and tetrahydrocannabivarin (THCV) for use in the treatment of an inflammatory skin disease is provided. The inflammatory skin disease is preferably selected from a microbial infection-induced dermatitis, a solar dermatitis or an atopic dermatitis. The cannabinoid may be in the form of a highly purified extract of cannabis such that it is present at greater than 95% of the total extract (w/w), or it may be synthetically produced. Preferably the cannabinoid is used at a dose of between and 10 and 1000mg and may be administered concomitantly with one or more medicaments, in particular corticosteroids.

Drugs covered by this patent

Patent Metadata

Patent number
GB2542797A
Jurisdiction
GB
Classification
—
Expires
2017-04-05
Drug substance claim
No
Drug product claim
No
Assignee
GW Pharma Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.